Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

GSK Pharmaceuticals - Analyst call highlights - Sep 28, 2020 - ICICI Securities

Posted On: 2020-09-28 22:43:16


GlaxoSmithKline Pharmaceuticals Limited's (GSKP) held a virtual analyst meet to discuss company's performance. We cover the highlights below:

- Company believes its key brands and therapies would continue to grow over the next five years. Company has witnessed that most of its key brands have outpaced their respective industries and gained market share.

- Vaccines remains an important growth area followed by respiratory. It will also invest in therapies like oncology but that would take time to scale up. Vaccine contributes ~23% of revenue and is expected to grow in double digits. It's imported and has lower margin than the company but it would be supported by cost optimisation.

- Company has received approval for Augmentin ES600, Trelegy and Fluarix Tetra and has filed for Shingrix, Rotarix liquid oral vaccine and Nucala liquid pediatric indication to support growth over long term. In the near term it is focusing on Nucala and Menveo.

- Company has witnessed a contraction in the dermatology and anti-infective market as patients defer skin treatment and better hygiene has reduced the acute illness.

- Pandemic caused disruption at the beginning of the lockdown. Company implemented several safety protocols and work from home policy wherever possible. Gradually, ~60% of the workforce was able to achieve ~100% production. Roughly 4,000 employees are working from home. Company witnessed MoM recovery in all therapies and expect to achieve normalcy soon. Company also provided extended credits to its partners (stockists, dealers, etc.) in order to support the system.

- Company initiated several cost rationalisation steps including zero based budgeting, in order to reduce financial burden. Company is considering upskilling and redeployment in required areas for employees instead of rationalisation.

- During the lockdown company remain connected with healthcare professionals (HCPs) digitally. Ground field force quickly adapted to the new environment and digital outreach ensured business continuity. Digital medium would remain an important mode of communication and post normalisation would be an effective tool to increase its reach across the country.

- Export is not an opportunity for the company because there is a disparity between the product basket in India and other markets. Another reason is that the price disparity is too large between geographies.

- Company is considering all viable options for Vemgal plant. Company would continue to out-source some level of manufacturing and believes that they have built a strong relationship with the CMOs over time for financial viability.

- Data readout for the global trials of COVID-19 vaccine is expected by the end of the year or early next year. Currently, it's too soon for a strategy or roadmap to bring the vaccine to India. However, the opportunity remains too large to be dismissed.

Valuations and risks: GSKP's exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well for the company. Recent correction has made valuations fair, hence we upgrade to HOLD from Reduce with a target price of Rs1,539/share based on 40xSep'22E EPS. Key downside risks: addition of key drugs in National List of Essential Medicines (NLEM), product concentration and government intervention. Key upside risks: better than expected performance in key products and launch of COVID-19 vaccine in India.

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs.1578 as compared to the previous close of Rs. 1544.1. The total number of shares traded during the day was 6279 in over 928 trades.

The stock hit an intraday high of Rs. 1589.25 and intraday low of 1530. The net turnover during the day was Rs. 9827984.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Reiterate ADD on Amara Raja Batteries - Pent-up demand leads to healthy 2Q - HDFC Securities

Maintain REDUCE on Titan - Reasonable print - HDFC Securities

REDUCE on RBL Bank - Some positives, but key concerns remain - HDFC Securities

Maintain REDUCE on Marico - Saffola shines with PCNO recovery, muted margin - HDFC Securities

Maintain ADD on Dr. Reddy's Labs - Good quarter, lower SG&A cost is encouraging - HDFC Securities

Piramal Enterprises - Acquisition of stake from JV partner - Angel Broking

Maintain BUY on Axis Bank - Provision buffers strengthened (further) - HDFC Securities

AU Small Finance Bank - Q2FY21 Result - Angel Broking

L&T - Q2FY21 - Angel Broking

RBL Bank - Q2FY21 Result - Angel Broking

Axis Bank - Q2FY21 Result - Angel Broking

Marico Ltd - Q2FY21 Result Update - YES Securities

Titan Company Ltd - Q2FY21 Result Update - YES Securities

Axis Bank Limited - Q2FY21 Result Update - YES Securities

RBL Bank Limited - Q2FY21 Result Update - YES Securities

Multi Commodity Exchange of India - Operating leverage aids strong EBITDA performance - ICICI Securities

Titan Company - Faster-than-expected recovery - ICICI Securities

Marico - Strong performance across portfolio - ICICI Securities

Heritage Foods - Lower procurement prices leading to highest EBITDA margin in past decade - ICICI Securities

Axis Bank - Strong core again utilised to create provisioning buffer - ICICI Securities

Supreme Industries - Beat on all counts - ICICI Securities

GSK Pharmaceuticals - Recovery from COVID-19 impact - ICICI Securities

Hero MotoCorp - Solid demand recovery expectations priced in - ICICI Securities

Cement - Demand / prices improve further in Oct'20 - ICICI Securities

CEAT - Replacement demand drives outperformance - ICICI Securities

Dr. Reddy's Laboratories - Outperformance continues - ICICI Securities

ICICI Prudential Life Insurance - VNB trajectory in-line despite YoY dip in protection in Q2 - ICICI Securities

Bharti Airtel - Q2FY21 Result Update - ICICI Securities

Marico - Q2FY21 Result Update - ICICI Securities

Larsen & Toubro - Q2FY21 First Cut - ICICI Securities

Sanofi India - Q3CY20 Company Update - ICICI Securities

Adani Ports and SEZ - Quant Pick - ICICI Securities

Nippon Life India AMC - Q2FY21 Result Update - ICICI Securities

Tata Motors - Q2FY21 Result Update - ICICI Securities

Derivatives Strategy - Mahanagar Gas - Positional Future - ICICI Securities

Supreme Industries - Q2FY21 First Cut - ICICI Securities

Dr Reddy's Laboratories - Q2FY21 First Cut - ICICI Securities

Marico Ltd - Q2FY21 First Cut - ICICI Securities

Apcotex Industries - Q2FY21 First Cut - ICICI Securities

V-Guard Industries - Q2FY21 First Cut - ICICI Securities

Titan Company - Q2FY21 First Cut - ICICI Securities

Navin Fluorine - Q2FY21 First Cut - ICICI Securities

PI Industries - Q2FY21 First Cut - ICICI Securities

L&T - Q2FY21 Earnings First Cut: Beat on EBITDA margins - YES Securities

Bharti Airtel - Q2FY21 result - Angel Broking

Dr.Reddy's Lab - Q2FY21 - Angel Broking

BUY on Mahindra & Mahindra Financial Services - Remains an inexpensive rural play - HDFC Securities

Radico Khaitan - Q2FY21 - Angel Broking

Maintain BUY on CDSL - Firing on all cylinders - HDFC Securities

REDUCE on Nippon Life India Asset Management - Market share stabilising - HDFC Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019